Treatment of patients with leukemia using NK cells

Phase 1

Recruiting

• Conditions: Condition 1: Acute lymphoblastic leukemia (ALL). Condition 2: Chronic lymphocytic leukemia (CLL).; Acute lymphoblastic leukaemia; Chronic lymphocytic leukaemia

• Registration Number: IRCT2017083027520N9
• Lead Sponsor: Stem Cell And Regenerative Medicine Institute

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 10

Inclusion Criteria

1-Age range of 18- 25 years for ALL patients; 2-Age range over 50 years for patients with CLL; 3- Those who have a proper cell donors with incongruent KIR (Haploidentical KIR-L mismatched donor); 4- Patients with adequate organ function; 5-Access to the patient for the continuation of treatment and follow-up (preferably from Azeri-speaking patients for easier access and removal of the Zentique variable);
Exclusion criteria : 1-Patients with active and uncontrolled infections; 2-Abnormal kidney, lung and liver function, measured by serum creatinine (serum creatinine> 2 mg / dl), saturated oxygen O2 = 96%) (Sat and liver enzymes (ALT / AST> 2.5 x N); 3-Patients with Down syndrome; 4- Patients with acute promyelocytic leukemia

Exclusion Criteria

Not provided

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Phenotype and function of NK cells. Timepoint: 2, 7, 14, 21 and 28 days after the transplant. Method of measurement: Flow cytometry.

Secondary Outcome Measures

Name	Time	Method
IFN?. Timepoint: 2, 7, 14, 21 and 28 days after the transplant. Method of measurement: Flow cytometry.;CD107. Timepoint: 2, 7, 14, 21 and 28 days after the transplant. Method of measurement: Flow cytometry.